



Key Messages

Nirmatrelvir/ritonavir (Paxlovid):

- is an antiviral treatment for mild-moderate COVID-19 in people identified as at high risk for serious illness
- must be initiated within 5 days of symptom onset
- has several contraindications (comorbidity and drug interactions) which must be considered as part of the clinical assessment for eligibility
- has complex drug interactions which necessitates that **at least two drug interaction resources** be consulted and, optimally, reviewed by a pharmacist as part of the health care team

Resources

British Columbia COVID-19 Therapeutics Committee Resources

[COVID-19 Clinical Care: Treatments](#)

[Clinical Practice Guide: Recommendations and Evidence for the Use of Therapeutics in Mild-Moderate COVID-19](#)

[Practice Tool #1: Step-by-Step Assessment Guide for Clinicians](#)

[Practice Tool #2: Definitions of Clinically Extremely Vulnerable \(CEV\)](#)

[Practice Tool #3: Drug-Drug Interactions & Contraindications](#)

[Practice Tool #4: Nirmatrelvir/ritonavir \(Paxlovid\) Counselling Checklist](#)

[Health Care Provider Information - nirmatrelvir/ritonavir, remdesivir, sotrovimab](#)

Drug Interaction Resources (consult at least 2 resources)

[University of Liverpool COVID-19 Drug Interactions](#)

[Practice Tool # 3: Drug-Drug Interactions and Contraindications](#)

[Lexicomp®](#)

[Paxlovid and Antiretrovirals: BC Centre for Excellence in HIV/AIDS](#)

Prescription

Fillable PDF: [Nirmatrelvir/ritonavir \(Paxlovid\) 5-day Treatment Pack Prescription](#)

eforms prescription: [Provincial eForms Login page](#) (requires sign-in)

Support Lines for BC Clinicians

Rapid Expert Advice and Consultation for HIV (REACH) Line: **1-800-665-7677**

BC Cancer: Regional BC Cancer Centre pharmacists are available Monday - Friday 8 AM - 4 PM (PT) (see contact information on pages 12 or 13 of [Practice Tool #1](#))